Last updated: April 22, 2024
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Overall Status: Active - Recruiting
Phase
2
Condition
Biliary Tract Cancer
Liver Cancer
Digestive System Neoplasms
Treatment
Adebrelimab, Apatinib, Gemcitabine, cisplatin
Clinical Study ID
NCT06280508
SYSKY-2024-082-01
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- confirmed intrahepatic cholangiocarcinoma
- with Resectable tumor lesion
- no contraindications to surgery
- with high risk of tumour recurrence
- No prior systemic therapy for intrahepatic cholangiocarcinoma.
- ECOG Performance Status of 0 or 1
- Child-Pugh Class: Grade A
Exclusion
Exclusion Criteria:
- History of gastrointestinal hemorrhage within 6 months prior to the start of studytreatment or clear tendency of gastrointestinal hemorrhage
- Abdominal fistula, gastrointestinal perforation or intraperitoneal abscess within 6months prior to the start of study treatment
- Known genetic or acquired hemorrhage or thrombotic tendency
- Thrombosis or thromboembolic event within 6 months prior to the start of studytreatment
- Cardiac clinical symptom or disease that is not well controlled
- Hypertension that can not be well controlled through antihypertensive drugs
Study Design
Total Participants: 40
Treatment Group(s): 1
Primary Treatment: Adebrelimab, Apatinib, Gemcitabine, cisplatin
Phase: 2
Study Start date:
March 01, 2024
Estimated Completion Date:
March 31, 2028
Connect with a study center
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangzhou, China/Guangdong
ChinaActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.